Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 30, 2025, titled "Completion of Acquisition of Checkpoint Therapeutics".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma has completed the acquisition of Checkpoint Therapeutics, Inc., a US-based immunotherapy and targeted oncology company. The deal was first announced in March 2025 and has now been finalised. Through this acquisition, Sun Pharma gains UNLOXCYTTM (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC), a common skin cancer. Sun Pharma paid $4.10 per share in cash, plus a non-tradable contingent value right (CVR) per share that could pay up to an additional $0.70 in cash if certain milestones are met. This move strengthens Sun Pharma's specialty and onco-dermatology portfolio, which already accounts for over 18% of company sales.
This is a positive, growth-oriented move that adds a revenue-generating, FDA-approved oncology product to Sun Pharma's specialty portfolio. It expands the company's presence in the US onco-derm market but also adds cash outflow and integration risk. Investors may see this as a strategic boost to long-term specialty growth, though near-term stock impact is likely to be muted since the deal was already known.